ONCY Oncolytics Biotech Inc.
0.5958USD-0.37%Mkt Cap: 75.97M $P/E: —1d ago
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunot…
Industry Peers
Biotechnology$128.08BUSDP/E 29.4
$78.44BUSD
$76.40BUSDP/E 18.4
$57.03BUSDP/E 37.3
$58.08BUSDP/E 35.4
$42.24BUSDP/E 18.0
$43.05BUSD
$41.41BUSDP/E 65.1
$32.80BUSDP/E 30.2
$30.03BUSDP/E 37.8
$25.10BUSD
$23.93BUSD
$22.99BUSDP/E 14.5
$22.27BUSDP/E 30.7
$22.54BUSDP/E 28.9
$22.22BUSD
$15.03BUSDP/E 17.5
$15.01BUSDP/E 15.8
$14.48BUSDP/E 18.4
$14.32BUSD
| Headline | Source | Time |
|---|---|---|
Older | ||
 3 Clinical-Stage Cancer Stocks With Pristine Balance Sheets Rising rates raise the bar for risky science. Meet three clinical-stage cancer stocks with pristine, debt-free balance sheets, plus the screener that surfaces the rest. | ||
 3 Small Cap Biotech Stocks Trading At A Discount With Late Stage Clinical Catalysts Looking for biotech stocks with upside that could help people fight illness? Here are three that analysts think might be worth a look. | ||
 Why Oncolytics Biotech Just Cleared A Hurdle That Stalls Most Cancer Trials Oncolytics Biotech has received FDA feedback supporting a potential pivotal expansion of its REO 033 colorectal cancer trial. | ||
 Oncolytics Biotech Shares Climb Ahead of Planned FDA Meeting on REO 033 Trial (ONCY) Stock Gains on Regulatory DevelopmentOncolytics Biotech Inc. (NASDAQ:ONCY) shares rose 5. | ||